Zhang Ingrid purchased $163K of LEGN

Zhang Ingrid (Chief Executive Officer) purchased 20,000 shares of Legend Biotech Corp (LEGN) at $8.16 ($0.16M total) on 2026-11-17.

Original reporting
SEC EDGAR · Zhang Ingrid
Published Nov 20, 2026, 9:10 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 20, 2026, 9:24 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$LEGN
Bullish
medium confidence
Mentioned
$LEGN
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LEGNBullishLow
01

Why it matters

This provides incremental sentiment information about management’s positioning, but it does not include any new company guidance, trial results, regulatory action, or deal terms.

02

Market read

Traders may note mild bullish sentiment from CEO buying, but the disclosure alone is unlikely to drive a sustained repricing without accompanying fundamental news.

03

What to watch

The filing states no pre-arranged 10b5-1 plan, but the article does not provide whether the purchase was funded by prior sales, compensation timing, or tax planning, which can reduce signal strength.

Relevance 5/10Novelty 5/10Timing: filed 2026-11-20, covering purchase dated 2026-11-17

Background

The article is an SEC Form 4 insider transaction disclosure for Legend Biotech, reporting a CEO open-market purchase.

Company-level read

Ticker impact

$LEGNBullishMedium confidence
Context

Legend Biotech CEO Zhang Ingrid filed a Form 4 for an open-market purchase of 20,000 shares at $8.1600 on 2026-11-17.

Expected impact

Likely limited near-term impact, with traders treating it as mild bullish sentiment rather than a driver of earnings or guidance.

Evidence & confidence

The disclosure is a primary SEC Form 4, but the article provides only a single purchase size and price, with no accompanying operational or financial change.

Market effects

Minimal, as this is an individual insider transaction with no disclosed sector-wide development.

None indicated.

None indicated.

Counterpoint

CEO open-market buys can be routine liquidity or diversification activity and may not signal a change in fundamentals, especially without additional context on motives.

Key entities

  • Legend Biotech Corp

    US-listed biotech company subject of the Form 4 insider transaction.

  • Zhang Ingrid

    Chief Executive Officer who purchased shares via an open-market transaction.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$LEGNMedAI 8/10

Legend Biotech (LEGN) Q3 2026 Earnings Call Transcript

Legend Biotech (LEGN) reported Q3 2026 earnings, with CARVYKTI net trade sales up 36% YoY to $710M. Growth driven by U.S. and international adoption. The company presented long-term data supporting CARVYKTI's use in earlier multiple myeloma lines and received FDA clearance for LB2501. Legend Biotech aims for profitability in 2026 and has $853M in cash reserves.

$LEGNMedAI 8/10

Legend Biotech Corp (LEGN) Q3 2026 Earnings Call Highlights: CARVYKTI Sales Jump 36%

Legend Biotech (LEGN) reported a 36% increase in CARVYKTI sales for Q3 2026, but U.S. sales were flat. Management noted slower-than-expected U.S. growth and launch delays in ex-U.S. markets. R&D expenses declined 16% year-over-year, but future spending may increase. CARVYKTI's U.S. sales mix shifted toward earlier lines, and the company expects double-digit growth in 2027. LB2501 dose level 3 showed lower efficacy than dose level 2, and there were no updates on LB2505.

$LEGNMed

What Legend Biotech (LEGN) Said on Its Q3 Earnings Call

Legend Biotech (LEGN) reported a 32% year-over-year revenue increase, with adjusted net income of $55.6M. CEO Ingrid Zhang expects CARVYKTI to generate over $5B in peak sales. The company improved gross margins and reduced R&D expenses. Legend also received FDA clearance for a clinical study of LB2501 and shared positive interim data. The company remains debt-free with $853M in cash equivalents.

$LEGNHigh

Why is Legend Biotech stock sliding today?

Legend Biotech (LEGN) stock fell 13.2% pre-market after reporting a Q3 2026 GAAP loss of $0.13 per share, missing estimates. Revenue of $359.5M beat expectations, but license revenue declined. The company announced a new CEO and FDA clearance for LB2501, but these were overshadowed by the earnings miss and broader market declines.

$LEGNMed

Legend Biotech shares fall 2% despite revenue beat

Legend Biotech (LEGN) reported Q3 2026 revenue of $359.5M, beating estimates. Shares fell 2.18% despite results. Collaboration revenue rose to $353.2M, driven by CARVYKTI sales. Net income was $51.7M, reversing a prior-year loss. R&D and admin expenses declined. FDA cleared IND for LB2501. Cash reserves were $853M.